Literature DB >> 1984814

Mechanism of bronchodilator effect in chronic airflow limitation.

R Jaeschke1, G H Guyatt, J Singer, J Keller, M T Newhouse.   

Abstract

OBJECTIVE: To examine the mechanisms through which two bronchodilators (theophylline and salbutamol) influence dyspnea during daily activities.
METHODS: Twenty-four patients with chronic airflow limitation participated in a multiple crossover, randomized, placebo-controlled trial. The effect of theophylline and salbutamol, alone or combined, on pulmonary function and dyspnea during daily activities was examined. Correlations of changes in forced expiratory volume in 1 second (FEV1) and maximum expiratory pressures (MIPs) (independent variables) and changes in dyspnea score during daily activities (dependent variable) were also examined.
RESULTS: The two drugs proved to be beneficial the effects in general were additive rather than synergistic. The drugs improved the FEV1; theophylline significantly improved the MIPs. The correlation between the changes in FEV1 and those in dyspnea score, after adjustment for the changes in MIPs, was 0.55 (p less than 0.001). The correlation between the changes in MIPs and those in dyspnea score, after adjustment for the changes in FEV1, was 0.39 (p less than 0.001).
CONCLUSIONS: Changes in airway calibre and in respiratory muscle strength play an independent and important role in dyspnea during daily activities in patients with chronic airflow limitation. Changes in airway calibre may be of greater importance.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1984814      PMCID: PMC1452523     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  13 in total

1.  Acute response to bronchodilator. An imperfect guide for bronchodilator therapy in chronic airflow limitation.

Authors:  G H Guyatt; M Townsend; S Nogradi; S O Pugsley; J L Keller; M T Newhouse
Journal:  Arch Intern Med       Date:  1988-09

2.  A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease.

Authors:  D Murciano; M H Auclair; R Pariente; M Aubier
Journal:  N Engl J Med       Date:  1989-06-08       Impact factor: 91.245

3.  Measurement of health status. Ascertaining the minimal clinically important difference.

Authors:  R Jaeschke; J Singer; G H Guyatt
Journal:  Control Clin Trials       Date:  1989-12

4.  Families of lines: random effects in linear regression analysis.

Authors:  H A Feldman
Journal:  J Appl Physiol (1985)       Date:  1988-04

5.  High dose salbutamol in chronic bronchitis: comparison of 400 micrograms, 1 mg, 1.6 mg, 2 mg and placebo delivered by Rotahaler.

Authors:  S C Jenkins; J Moxham
Journal:  Br J Dis Chest       Date:  1987-07

6.  A measure of quality of life for clinical trials in chronic lung disease.

Authors:  G H Guyatt; L B Berman; M Townsend; S O Pugsley; L W Chambers
Journal:  Thorax       Date:  1987-10       Impact factor: 9.139

7.  Theophylline and diaphragmatic contractility. Investigation of a dose-response relationship.

Authors:  J W Foxworth; G R Reisz; S M Knudson; P G Cuddy; D R Pyszczynski; C E Emory
Journal:  Am Rev Respir Dis       Date:  1988-12

8.  Respiratory pressures and function in young adults.

Authors:  J A Leech; H Ghezzo; D Stevens; M R Becklake
Journal:  Am Rev Respir Dis       Date:  1983-07

9.  Dose-response study of inhaled salbutamol powder in chronic airflow obstruction.

Authors:  P A Corris; E Neville; S Nariman; G J Gibson
Journal:  Thorax       Date:  1983-04       Impact factor: 9.139

10.  Measuring functional status in chronic lung disease: conclusions from a randomized control trial.

Authors:  G H Guyatt; M Townsend; J Keller; J Singer; S Nogradi
Journal:  Respir Med       Date:  1989-07       Impact factor: 3.415

View more
  3 in total

Review 1.  Quality of life instruments in the evaluation of new drugs.

Authors:  R Jaeschke; G H Guyatt; D Cook
Journal:  Pharmacoeconomics       Date:  1992-02       Impact factor: 4.981

Review 2.  Regular inhaled short acting beta2 agonists for the management of stable chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis.

Authors:  F S F Ram; P Sestini
Journal:  Thorax       Date:  2003-07       Impact factor: 9.139

3.  Prescription Status and Clinical Outcomes of Methylxanthines and Leukotriene Receptor Antagonists in Mild-to-Moderate Chronic Obstructive Pulmonary Disease.

Authors:  Jung-Kyu Lee; Chin Kook Rhee; Kyungjoo Kim; Seung Won Ra; Jae Ha Lee; Ki-Suck Jung; Kwang Ha Yoo; Yoo-Il Kim; Deog Kyeom Kim
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-11-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.